RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Norway has reported 23 deaths related to vaccination against the COVID-19 infection. 13 of the deaths have been assessed, with the results suggesting that common side effects may have contributed to severe reactions in frail, elderly people, according to the Norwegian Agency for Medicines said January 14.
Over 25,000 people have been vaccinated in the country since the drive began on December 27 last year, Pfizer’s (PFE -0.3%) mRNA- based vaccines were used in the concerned cases.
The report cited of the 13 deaths, nine serious and seven less serious side effects were reported.
The casualties were all among those with advanced heart conditions, dementia, chronic obstructive pulmonary disease and other serious diseases and aged at least 80 and some more than 90 years.
Pfizer and BioNTech are working with the Norwegian regulator to investigate the deaths in Norway. The agency found that “the number of incidents so far is not alarming, and in line with expectations,” Pfizer said.
Pfizer also plans to reduce European vaccine deliveries as its upgrades production capacity.
After a ~9.9% rise in value yesterday, Sorrento Therapeutics (NASDAQ:SRNE) has added another ~8.9% so far today, and an analyst from H.C. Wainwright estimates a price target of ~$30 for the stock, implying a ~275.0% upside to yesterday’s close.
The analyst Ram Selvaraju projects $321M in total for Sorrento’s investments in Celularity, a clinical-stage cell therapeutics company, and NantKwest (NASDAQ:NK), which recently climbed in value in response to impressive mid-stage trial data in advanced pancreatic cancer.
Once merged with GX Acquisition Corp. (NASDAQ:GXGX) to go public, the stake at Celularity will be worth $200M Ram estimates, adding another $121M for the investment in NantKwest based on its current share price.
The analyst also highlights Sorrento’s “burgeoning portfolio of assets spanning three distinct therapeutic areas (non-opioid pain management, oncology, and COVID-19).”
Late December, Sorrento filed the Emergency Use Authorization (“EUA”) application for its COVI-STIX rapid diagnostic test for the detection of the SARS-CoV-2 virus.
TPCO Holding Corp., formerly Subversive Capital Acquisition Corp.(OTCQX:SBVCF), has closed its acquisition of CMG Partners Inc. (“Caliva”), and Left Coast Ventures, Inc. in creating what is considered as the most well-capitalized cannabis company in the U.S.
The common shares and warrants will remain trading on the OTCQX under the symbols “SBVCF” and “SBVQF,” before changing the “SBVCF” symbol to “GRAMF” effective January 19, 2021.
Michael Auerbach, Chairman of SCAC says: “the parent company will help shape the future of cannabis in the U.S. and beyond as well as begin to repair and rectify the wrongs of prohibition.”
The parent company (TPCO Holding Corp.) is California’s leading vertically integrated cannabis company and has Shawn “JAY-Z” Carter as the chief visionary officer, an announcement from TPCO said.
